Vrtovec Katja Triller, Vrtovec Bojan
Max Planck Institute for Intellectual Property, Competition and Tax Law, München, Germany.
Stem Cells. 2007 Dec;25(12):3026-8. doi: 10.1634/stemcells.2007-0511. Epub 2007 Aug 30.
This article argues that totipotent character of human totipotent cells--defined as the capacity of a cell "to differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta"--is not a sufficient reason to exclude their patentability on the basis of Article 5(1) of the Directive 98/44/EC on the Legal Protection of Biotechnological Inventions (Biopatent Directive), which maintains that "the human body, at the various stages of its formation and development, [...] cannot constitute patentable inventions." Since human totipotent cells have both the potential to generate an entire new organism or to generate only different tissues or organs of an organism, they simultaneously fit the definition of the unpatentable human body at the earliest stage of its formation as well as of an element of the human body, which "may constitute a patentable invention" pursuant to Article 5(2) of the Biopatent Directive, whether that element is isolated from the human body or otherwise produced by means of a technical process. Therefore, this article suggests that, when evaluating patentability of human totipotent cells, they should be further evaluated according to their location and their method of derivation (i.e., whether human totipotent cells are located in the human body, whether they are isolated from the human body, or whether they are produced otherwise by means of a technical process). Disclosure of potential conflicts of interest is found at the end of this article.
本文认为,人类全能细胞的全能特性(定义为细胞“分化为所有体细胞谱系(外胚层、中胚层、内胚层)、生殖系以及胎盘等胚外组织的能力”)并非基于98/44/EC号关于生物技术发明法律保护的指令(生物专利指令)第5(1)条而排除其可专利性的充分理由,该条规定“人体在其形成和发育的各个阶段,[...]不能构成可专利发明”。由于人类全能细胞既有产生全新生物体的潜力,也有仅产生生物体不同组织或器官的潜力,它们既符合不可专利的人体在其形成最早阶段的定义,也符合人体的一个要素的定义,而根据生物专利指令第5(2)条,该要素“可以构成可专利发明”,无论该要素是从人体分离出来的还是通过技术过程以其他方式产生的。因此,本文建议,在评估人类全能细胞的可专利性时,应根据它们的位置及其衍生方法(即人类全能细胞是位于人体内、从人体分离出来的,还是通过技术过程以其他方式产生的)进行进一步评估。潜在利益冲突的披露见本文末尾。